Scott Megaffin Adastra's guest appearances

Scott Megaffin Adastra

Empowered Patient Podcast

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well. #Glioblastoma #braintumor #drugdevelopment #braincancer #NCI AdastraRx.com Download the transcript here

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well. #Glioblastoma #braintumor #drugdevelopment #braincancer #NCI <a href="http://adastrarx.com" rel="noopener nofollow" target="_blank">AdastraRx.com</a> <a href="http://empoweredpatientradio.com/developing-potent-oral-kinase-inhibitor-to-treat-recurrent-difficult-to-treat-brain-cancer-with-scott-megaffin-adastra-pharmaceuticals-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Developing Potent Oral Kinase Inhibitor to Treat Recurrent Difficult to Treat Brain Cancer with Scott Megaffin Adastra Pharmaceuticals